Cadila Healthcare plans to launch molecule for diabetes dyslipidemia: Report

19 Mar 2013 Evaluate

Cadila Healthcare, part of the ZydusCadila group, is reportedly planning to launch an indigenously developed molecule for diabetes dyslipidemia, which is expected to be called Saroglitizar. The company has been working on a new molecule since 2004. At present, the company has several molecules under its research pipeline which it hopes to bring to the market.

Recently, Zydus Cadila received tentative approval from USFDA for Doxepin Hcl tablets in the strengths of 3 mg and 6 mg. The estimated sale in 2012 as per IMS for Doxepin Hcl, which falls in the neuropsychiatry segment, was $15.5 million.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×